
ROIV Stock Forecast & Price Target
ROIV Analyst Ratings
Bulls say
Roivant Sciences is a commercial-stage biopharmaceutical company that has a promising future due to its diverse portfolio of drug candidates and business model that both support growth potential. The company has experienced strong financial performance, with an increase in revenue and decrease in expenses in its most recent quarter. Additionally, Roivant's management team appears confident in the potential of its drug candidates, as evidenced by the successful enrollment in its Phase 2 study and plans for commercial launches and proof-of-concept readouts. With strong cash reserves and multiple catalysts on the horizon, Roivant Sciences is well-positioned for continued success in the biopharmaceutical industry.
Bears say
Roivant Sciences is facing significant challenges with its drug candidates Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others still in various stages of development and a projected launch date of September 2026 for their most advanced drug dermatomyositis (DM). While the recent success of IMVT-1402 in D2TRA may have improved sentiment towards the company, it is still too early to accurately predict future success. Additionally, the potential combination strategy of mosliciguat and treprostinil in PH-ILD may face difficulties in the current competitive market.
This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.
ROIV Analyst Forecast & Price Prediction
Start investing in ROIV
Order type
Buy in
Order amount
Est. shares
0 shares